Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in Oncologist Retrieve available abstracts of 118 articles: HTML format

Single Articles

April 2024
1. CHEN HW, Kuo YW, Chen CY, Chang CH, et al
   Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy.
   Oncologist. 2024;29:e498-e506.
   PubMed     Abstract available
   
   
   
2. ARRIOLA E, Jaal J, Edvardsen A, Silvoniemi M, et al
   Feasibility and User Experience of Digital Patient Monitoring for Real-World Patients With Lung or Breast Cancer.
   Oncologist. 2024;29:e561-e569.
   PubMed     Abstract available
   
   
   
3. ALLENDE S, Turcott JG, Verastegui E, Rodriguez-Mayoral O, et al
   Early Incorporation to Palliative Care (EPC) in Patients With Advanced Non-Small Cell Lung Cancer: The PACO Randomized Clinical Trial.
   Oncologist. 2024 Apr 1:oyae050. doi: 10.1093.
   PubMed     Abstract available
   
   
   March 2024
4. XU Y, Ji H, Zhang Y, Xiong L, et al
   Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer.
   Oncologist. 2024 Mar 25:oyae052. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. PASELLO G, Lorenzi M, Scattolin D, Del Conte A, et al
   Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.
   Oncologist. 2024 Mar 23:oyae043. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. XU Y, Wen N, Haddad RI, Sonis ST, et al
   Comparisons of Non-Oral Immune-Related Adverse Events Among Patients With Cancer With Different Oral Toxicity Profiles.
   Oncologist. 2024;29:e382-e391.
   PubMed     Abstract available
   
   
   February 2024
7. STRICKER T, Jain N, Ma E, Yu E, et al
   Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.
   Oncologist. 2024 Feb 28:oyae022. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. BRIA E, Morgillo F, Garassino MC, Ciardiello F, et al
   Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial.
   Oncologist. 2024 Feb 20:oyad342. doi: 10.1093.
   PubMed     Abstract available
   
   
   January 2024
9. KATAYAMA Y, Yamada T, Sawada R, Kawachi H, et al
   Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.
   Oncologist. 2024 Jan 18:oyae001. doi: 10.1093.
   PubMed     Abstract available
   
   
   
10. GERBER DE, Wang Y, Ramalingam SS, Bhalla S, et al
    Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer.
    Oncologist. 2024 Jan 11:oyad335. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. WANG H, Fan Z, Yang X, Wu Q, et al
    Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non-small Cell Lung Cancer: A Case Report.
    Oncologist. 2024 Jan 10:oyad339. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. BONANNO L, Lorenzi M, Massa D, De Nuzzo M, et al
    Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting.
    Oncologist. 2024;29:e118-e130.
    PubMed     Abstract available
    
    
    
13. HORIUCHI K, Ikemura S, Sato T, Shimozaki K, et al
    Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis.
    Oncologist. 2024;29:e108-e117.
    PubMed     Abstract available
    
    
    
14. JORDAN J, Maki RG
    The Weighted Toxicity Score: Confirmation of a Simple Metric to Communicate Toxicity in Randomized Trials of Systemic Cancer Therapy.
    Oncologist. 2024;29:67-74.
    PubMed     Abstract available
    
    
    November 2023
15. 
    Correction to: Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
    Oncologist. 2023 Nov 24:oyad316. doi: 10.1093.
    PubMed    
    
    
    
16. STRICKLER JH, Yoshino T, Stevinson K, Eichinger CS, et al
    Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review.
    Oncologist. 2023;28:e981-e994.
    PubMed     Abstract available
    
    
    October 2023
17. HU X, Melson JW, Pan SS, Salei YV, et al
    Screening, Diagnosis, and Initial Care of Asian and White Patients With Lung Cancer.
    Oncologist. 2023 Oct 5:oyad272. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. SILVERSTEIN J, Wright F, Wang M, Young A, et al
    Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors.
    Oncologist. 2023;28:e950-e959.
    PubMed     Abstract available
    
    
    September 2023
19. SHANG X, Zhang C, Kong R, Zhao C, et al
    Construction of a Diagnostic Model for Small Cell Lung Cancer Combining Metabolomics and Integrated Machine Learning.
    Oncologist. 2023 Sep 14:oyad261. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. HASEGAWA T, Okuyama T, Uemura T, Matsuda Y, et al
    Elements of End-of-Life Discussions Associated With Patients' Reported Outcomes and Actual End-of-Life Care in Patients With Pretreated Lung Cancer.
    Oncologist. 2023 Sep 5:oyad245. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2023
21. ELKRIEF A, Riccuiti B, Alessi JV, Fei T, et al
    Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
    Oncologist. 2023 Aug 17:oyad197. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. GENTZLER RD, Villaruz LC, Rhee JC, Horton B, et al
    Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399.
    Oncologist. 2023 Aug 9:oyad221. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. HUNT AL, Nutcharoen A, Randall J, Papazian A, et al
    Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic Cancer.
    Oncologist. 2023;28:730-736.
    PubMed     Abstract available
    
    
    
24. FARHA N, Faisal MS, Allende DS, Sleiman J, et al
    Characteristics of Immune Checkpoint Inhibitor-Associated Gastritis: Report from a Major Tertiary Care Center.
    Oncologist. 2023;28:706-713.
    PubMed     Abstract available
    
    
    July 2023
25. SULLIVAN HW, O'Donoghue AC, Boudewyns V, Paquin RS, et al
    Patient Understanding of Oncology Clinical Trial Endpoints in Direct-to-Consumer Television Advertising.
    Oncologist. 2023;28:e542-e553.
    PubMed     Abstract available
    
    
    
26. WEI Y, Zheng L, Yang X, Luo Y, et al
    Identification of Immune Subtypes and Candidate mRNA Vaccine Antigens in Small Cell Lung Cancer.
    Oncologist. 2023 Jul 3:oyad193. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2023
27. GENTZLER RD, Mohindra NA, Jalal SI, Reckamp KL, et al
    Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175.
    Oncologist. 2023 Jun 30:oyad180. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. DUBE-PELLETIER M, Labbe C, Cote J, Pelletier-St-Pierre AA, et al
    Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2023 Jun 26:oyad182. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. SMYTH EN, John J, Tiu RV, Willard MD, et al
    Clinicogenomic factors and treatment patterns among patients with advanced non-small cell lung cancer with or without brain metastases in the United States.
    Oncologist. 2023 Jun 26:oyad170. doi: 10.1093.
    PubMed     Abstract available
    
    
    
30. JOHN AO, Ramnath N
    Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy.
    Oncologist. 2023 Jun 20:oyad125. doi: 10.1093.
    PubMed     Abstract available
    
    
    
31. MOORE AM, Nooruddin Z, Reveles KR, Koeller JM, et al
    Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration.
    Oncologist. 2023 Jun 19:oyad172. doi: 10.1093.
    PubMed     Abstract available
    
    
    
32. BAIJAL S, Crosbie P, Fenemore J, Desai K, et al
    Variations in Genomic Testing in Non-small Cell Lung Carcinoma: A Healthcare Professional Survey of Current Practices in the UK.
    Oncologist. 2023 Jun 13:oyad134. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. PRUIS MA, Krebs MG, Plummer R, De Vos F, et al
    A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer.
    Oncologist. 2023 Jun 1:oyad146. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2023
34. ALTAN M, Soto F, Zhong LL, Akhmedzhanov FO, et al
    Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience.
    Oncologist. 2023 May 8:oyad118. doi: 10.1093.
    PubMed     Abstract available
    
    
    
35. STENZINGER A, Cuffel B, Paracha N, Vail E, et al
    Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.
    Oncologist. 2023;28:e242-e253.
    PubMed     Abstract available
    
    
    
36. MATHIAS K, Rouhani S, Olson D, Bass AR, et al
    Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.
    Oncologist. 2023;28:440-448.
    PubMed     Abstract available
    
    
    
37. JOHNSON ML, Patel MR, Aljumaily R, Jones SF, et al
    A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies.
    Oncologist. 2023 May 2:oyad029. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2023
38. WANG C, Zhao K, Hu S, Dong W, et al
    Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis.
    Oncologist. 2023 Apr 28:oyad111. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. AGGARWAL C, Maity AP, Bauml JM, Long Q, et al
    A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer.
    Oncologist. 2023 Apr 26:oyad106. doi: 10.1093.
    PubMed     Abstract available
    
    
    
40. TANIMURA K, Uchino J, Kimura H, Hiranuma O, et al
    Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial.
    Oncologist. 2023 Apr 13:oyad013. doi: 10.1093.
    PubMed     Abstract available
    
    
    
41. HERZBERG BO, Manji GA
    KRAS: Druggable at Last.
    Oncologist. 2023;28:283-286.
    PubMed     Abstract available
    
    
    
42. DANZIGER N, Sokol ES, Graf RP, Hiemenz MC, et al
    Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay.
    Oncologist. 2023;28:319-326.
    PubMed     Abstract available
    
    
    
43. ICHT O, Leader A, Batat E, Yosef L, et al
    Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study.
    Oncologist. 2023 Apr 4:oyad061. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2023
44. CHEN Y, Yu J, Meng X
    Postoperative Radiotherapy in Completely Resected IIIA-N2 Non-small Cell Lung Cancer: Quit or Not?
    Oncologist. 2023 Mar 18:oyad066. doi: 10.1093.
    PubMed    
    
    
    
45. LI LX, Cappuzzo F, Matos I, Socinski MA, et al
    Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials.
    Oncologist. 2023 Mar 11:oyad043. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. ZHANG J, Johnson M, Barve M, Bazhenova L, et al
    Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib.
    Oncologist. 2023 Mar 9:oyad051. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2023
47. NOVELLO S, Califano R, Reinmuth N, Tamma A, et al
    RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.
    Oncologist. 2023 Feb 23:oyac264. doi: 10.1093.
    PubMed     Abstract available
    
    
    
48. 
    Correction to: Management of Lung Cancer in the Patient with Interstitial Lung Disease.
    Oncologist. 2023 Feb 9:oyad018. doi: 10.1093.
    PubMed    
    
    
    December 2022
49. BARLESI F, Isambert N, Felip E, Cho BC, et al
    Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-beta and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.
    Oncologist. 2022 Dec 26:oyac253. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. WOODFORD K, Koo K, Reynolds J, Stirling RG, et al
    Persisting Gaps in Optimal Care of Stage III Non-small Cell Lung Cancer: An Australian Patterns of Care Analysis.
    Oncologist. 2022 Dec 20:oyac246. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2022
51. FRANK AJ, Dagogo-Jack I, Dobre IA, Tait S, et al
    Management of Lung Cancer in the Patient with Interstitial Lung Disease.
    Oncologist. 2022 Nov 25:oyac226. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. CHIHARA Y, Takeda T, Goto Y, Nakamura Y, et al
    A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.
    Oncologist. 2022;27:903-e834.
    PubMed     Abstract available
    
    
    
53. YAO J, Bergsland E, Aggarwal R, Aparicio A, et al
    DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
    Oncologist. 2022;27:940-951.
    PubMed     Abstract available
    
    
    October 2022
54. 
    Expression of Concern: Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study.
    Oncologist. 2022 Oct 31. pii: 6782256. doi: 10.1093.
    PubMed    
    
    
    
55. MOHAMED L, Manjrekar S, Ng DP, Walsh A, et al
    The Effect of Biomarker Use on the Speed and Duration of Clinical Trials for Cancer Drugs.
    Oncologist. 2022;27:849-856.
    PubMed     Abstract available
    
    
    September 2022
56. ALVES PINTO I, de Oliveira Cavagna R, Virginio da Silva AL, Dias JM, et al
    EGFR Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil.
    Oncologist. 2022 Sep 13. pii: 6696863. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. HASEGAWA T, Okuyama T, Uemura T, Matsuda Y, et al
    Prognostic Awareness and Discussions of Incurability in Patients with Pretreated Non-Small Cell Lung Cancer and Caregivers: A Prospective Cohort Study.
    Oncologist. 2022 Sep 6. pii: 6693237. doi: 10.1093.
    PubMed     Abstract available
    
    
    
58. FUJIWARA Y, Takahashi Y, Okada M, Kishimoto T, et al
    Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma.
    Oncologist. 2022;27:e703-e722.
    PubMed     Abstract available
    
    
    August 2022
59. HSU ML, Murray JC, Psoter KJ, Zhang J, et al
    Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy.
    Oncologist. 2022 Aug 16. pii: 6668266. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. 
    Correction to: Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab.
    Oncologist. 2022 Aug 6. pii: 6657714. doi: 10.1093.
    PubMed    
    
    
    
61. OFFIN M, Rusch VW, Rimner A, Adusumilli PS, et al
    Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice.
    Oncologist. 2022;27:610-614.
    PubMed    
    
    
    July 2022
62. SAKURADA T, Nokihara H, Koga T, Zamami Y, et al
    Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study.
    Oncologist. 2022;27:e554-e560.
    PubMed     Abstract available
    
    
    
63. WANG J, Martin-Romano P, Cassier P, Johnson M, et al
    Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation.
    Oncologist. 2022;27:536-e553.
    PubMed     Abstract available
    
    
    
64. JAHANZEB M, Lin HM, Wu Y, Zhang P, et al
    Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
    Oncologist. 2022 Jul 4. pii: 6628677. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2022
65. IKEDA S, Kato T, Kenmotsu H, Ogura T, et al
    Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study.
    Oncologist. 2022 Jun 27. pii: 6618634. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. MACK PC, Klein MI, Ayers KL, Zhou X, et al
    Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
    Oncologist. 2022;27:476-486.
    PubMed     Abstract available
    
    
    
67. GANTZER J, Davidson G, Vokshi B, Weingertner N, et al
    Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.
    Oncologist. 2022;27:501-511.
    PubMed     Abstract available
    
    
    May 2022
68. HUANG RSP, Harries L, Decker B, Hiemenz MC, et al
    Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases.
    Oncologist. 2022 May 22. pii: 6590419. doi: 10.1093.
    PubMed     Abstract available
    
    
    
69. MURUGESAN K, Jin DX, Comment LA, Fabrizio D, et al
    Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer.
    Oncologist. 2022 May 22. pii: 6590420. doi: 10.1093.
    PubMed     Abstract available
    
    
    
70. ISAWA T, Toi Y, Sugawara S, Taguri M, et al
    Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
    Oncologist. 2022;27:e410-e419.
    PubMed     Abstract available
    
    
    April 2022
71. PASELLO G, Lorenzi M, Calvetti L, Oliani C, et al
    Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab.
    Oncologist. 2022 Apr 16. pii: 6569250. doi: 10.1093.
    PubMed     Abstract available
    
    
    
72. POPAT S, Hsia TC, Hung JY, Jung HA, et al
    Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).
    Oncologist. 2022;27:255-265.
    PubMed     Abstract available
    
    
    March 2022
73. LEMMON CA, Zabor EC, Pennell NA
    Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer.
    Oncologist. 2022 Mar 14. pii: 6548144. doi: 10.1093.
    PubMed     Abstract available
    
    
    
74. JIAN H, Wang K, Cheng Y, Ding L, et al
    Phase I Trial of a Third Generation EGFR Mutant-Selective Inhibitor (D-0316) in Patients with Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2022;27:163-e213.
    PubMed     Abstract available
    
    
    
75. TAN R, Yun C, Seetasith A, Sheinson D, et al
    Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer.
    Oncologist. 2022;27:236-243.
    PubMed     Abstract available
    
    
    
76. WELLS JC, Sidhu A, Ding K, Smoragiewicz M, et al
    Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials.
    Oncologist. 2022;27:e286-e293.
    PubMed     Abstract available
    
    
    
77. STURGILL EG, Misch A, Jones CC, Luckett D, et al
    Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings.
    Oncologist. 2022;27:175-182.
    PubMed     Abstract available
    
    
    
78. LORENZI M, Ferro A, Cecere F, Scattolin D, et al
    First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
    Oncologist. 2022;27:87-e115.
    PubMed     Abstract available
    
    
    
79. PENG W, Cao L, Chen L, Lin G, et al
    Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
    Oncologist. 2022;27:e116-e125.
    PubMed     Abstract available
    
    
    
80. PAVAN A, Ferro A, Fortarezza F, Schiavon M, et al
    Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation With Outcome.
    Oncologist. 2022;27:e199-e202.
    PubMed     Abstract available
    
    
    February 2022
81. MORABITO A, Manzo A, Montanino A, Rachiglio AM, et al
    Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion.
    Oncologist. 2022;27:7-12.
    PubMed     Abstract available
    
    
    
82. MOSKOVITZ M, Dudnik E, Shamai S, Rotenberg Y, et al
    ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.
    Oncologist. 2022;27:e76-e84.
    PubMed     Abstract available
    
    
    
83. MIKKELSEN MK, Lund CM, Vinther A, Tolver A, et al
    Effects of a 12-Week Multimodal Exercise Intervention Among Older Patients with Advanced Cancer: Results from a Randomized Controlled Trial.
    Oncologist. 2022;27:67-78.
    PubMed     Abstract available
    
    
    December 2021
84. LI J, Wang Q, Ge J, Tian Y, et al
    BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
    Oncologist. 2021;26:e2115-e2119.
    PubMed     Abstract available
    
    
    
85. ARRIETA O, Lara-Mejia L, Bautista-GonzAlez E, Heredia D, et al
    Clinical Impact of the COVID-19 Pandemic in Mexican Patients with Thoracic Malignancies.
    Oncologist. 2021;26:1035-1043.
    PubMed     Abstract available
    
    
    
86. OZA AM, Dubois F, Hegg R, Hernandez CA, et al
    A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors.
    Oncologist. 2021;26:e2254-e2264.
    PubMed     Abstract available
    
    
    November 2021
87. PETRILLO LA, Zhou AZ, Sullivan R, Volandes A, et al
    Knowledge About Risks, Benefits, and Curative Potential of Immunotherapy Among Patients with Advanced Cancer.
    Oncologist. 2021;26:e2090-e2093.
    PubMed     Abstract available
    
    
    
88. AMELOT A
    Regarding "Surgical Metastasectomy in the Spine: A Review Article".
    Oncologist. 2021;26:e2097.
    PubMed    
    
    
    
89. ZHANG G, Xia P, Zhao S, Yuan L, et al
    Gefitinib Combined with Cetuximab for the Treatment of Lung Adenocarcinoma Harboring the EGFR-Intergenic Region (SEC61G) Fusion and EGFR Amplification.
    Oncologist. 2021;26:e1898-e1902.
    PubMed     Abstract available
    
    
    October 2021
90. OSPINA AV, Bruges R, Mantilla W, Triana I, et al
    Impact of COVID-19 Infection on Patients with Cancer: Experience in a Latin American Country: The ACHOCC-19 Study.
    Oncologist. 2021;26:e1761-e1773.
    PubMed     Abstract available
    
    
    
91. CHEN X, Sheikh K, Nakajima E, Lin CT, et al
    Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
    Oncologist. 2021;26:e1822-e1832.
    PubMed     Abstract available
    
    
    
92. GAN HK, Millward M, Jalving M, Garrido-Laguna I, et al
    A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors.
    Oncologist. 2021;26:e1844-e1853.
    PubMed     Abstract available
    
    
    September 2021
93. MINCHOM A, Tan AC, Massarelli E, Subbiah V, et al
    Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-small Cell Lung Cancer in the Phase 1/2 LIBRETTO-001 Trial.
    Oncologist. 2021 Sep 15. doi: 10.1002/onco.13976.
    PubMed     Abstract available
    
    
    
94. ARAI D, Sato T, Nakachi I, Fujisawa D, et al
    Longitudinal Assessment of Prognostic Understanding in Advanced Lung Cancer Patients and Its Association with Their Psychological Distress.
    Oncologist. 2021 Sep 12. doi: 10.1002/onco.13973.
    PubMed     Abstract available
    
    
    
95. GOSSLING GCL, Chedid MF, Pereira FS, da Silva RK, et al
    Outcomes and Prognostic Factors of Patients with Metastatic Colorectal Cancer Who Underwent Pulmonary Metastasectomy with Curative Intent: A Brazilian Experience.
    Oncologist. 2021;26:e1581-e1588.
    PubMed     Abstract available
    
    
    August 2021
96. LIN S, Luo S, Gu D, Li M, et al
    First-line durvalumab in addition to etoposide and platinum for extensive-stage small cell lung cancer: a United States-based cost-effectiveness analysis.
    Oncologist. 2021 Aug 25. doi: 10.1002/onco.13954.
    PubMed     Abstract available
    
    
    
97. LORENZI M, Ferro A, Cecere F, Scattolin D, et al
    First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
    Oncologist. 2021 Aug 23. doi: 10.1002/onco.13951.
    PubMed     Abstract available
    
    
    
98. XIANG M, Yang X, Ren S, Du F, et al
    Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial.
    Oncologist. 2021 Aug 22. doi: 10.1002/onco.13950.
    PubMed     Abstract available
    
    
    July 2021
99. IVANOVIC M, Knez L, Herzog A, Kovacevic M, et al
    Immunotherapy for metastatic non-small cell lung cancer: Real-world data from an academic Central and Eastern European centre.
    Oncologist. 2021 Jul 19. doi: 10.1002/onco.13909.
    PubMed     Abstract available
    
    
    
100. LEE Y, Cho Y, Park EY, Park SY, et al
     One-step polymerase chain reaction-free nanowire-based plasma cell-free DNA assay to detect EML4-ALK fusion and to monitor resistance in lung cancer.
     Oncologist. 2021 Jul 17. doi: 10.1002/onco.13902.
     PubMed     Abstract available
     
     
     
101. TJONG MC, Doherty M, Tan H, Chan WC, et al
     Province-Wide Analysis of Patient Reported Outcomes for Stage IV Non-Small Cell Lung Cancer.
     Oncologist. 2021 Jul 3. doi: 10.1002/onco.13890.
     PubMed     Abstract available
     
     
     
102. GRAY J, Thompson JC, Carpenter EL, Elkhouly E, et al
     Plasma cell-free DNA genotyping-from an emerging concept to a standard-of-care tool in metastatic non-small cell lung cancer.
     Oncologist. 2021 Jul 3. doi: 10.1002/onco.13889.
     PubMed     Abstract available
     
     
     
103. GEORGE S, Bell EJ, Zheng Y, Kim R, et al
     The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.
     Oncologist. 2021;26:e1205-e1215.
     PubMed     Abstract available
     
     
     
104. AYERS KL, Mullaney T, Zhou X, Liu JJ, et al
     Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
     Oncologist. 2021;26:e1226-e1239.
     PubMed     Abstract available
     
     
     June 2021
105. LOI M, Alifano M, Scorsetti M, Nuyttens JJ, et al
     Judging a Fish by Its Ability to Climb a Tree? A Call for Novel Endpoints in the Appraisal of Ablative Local Treatments of Oligometastatic Cancer.
     Oncologist. 2021;26:e1085-e1086.
     PubMed    
     
     
     
106. VARLOTTO JM, Sun Z, Ky B, Upshaw J, et al
     A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study.
     Oncologist. 2021;26:523-532.
     PubMed     Abstract available
     
     
     May 2021
107. ALKREKSHI A, Tamaskar I
     Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection.
     Oncologist. 2021;26:e827-e830.
     PubMed     Abstract available
     
     
     
108. MIYAGAWA C, Takaya H, Sakai K, Nishio K, et al
     A Novel Malignant Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20: A Case Report and Literature Review.
     Oncologist. 2021;26:356-361.
     PubMed     Abstract available
     
     
     April 2021
109. KRUG K, Bossert J, Deis N, Krisam J, et al
     Effects of an interprofessional communication approach on support needs, quality of life and mood of advanced lung cancer patients: a randomized trial.
     Oncologist. 2021 Apr 16. doi: 10.1002/onco.13790.
     PubMed     Abstract available
     
     
     
110. PERAVALI M, Ahn J, Chen K, Rao S, et al
     Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small-Cell Lung Cancer.
     Oncologist. 2021 Apr 12. doi: 10.1002/onco.13787.
     PubMed     Abstract available
     
     
     
111. BERNICKER EH, Xiao Y, Abraham A, Yang B, et al
     Adherence to NCCN ALK testing guidelines for patients with advanced non-small cell lung cancer in US Community Medical Centers.
     Oncologist. 2021 Apr 6. doi: 10.1002/onco.13779.
     PubMed     Abstract available
     
     
     
112. JELINEK MJ, Aggarwal C
     Adjuvant Osimertinib: A New Standard of Care.
     Oncologist. 2021;26:263-265.
     PubMed    
     
     
     
113. VAN BRUMMELEN EMJ, Huijberts S, van Herpen C, Desar I, et al
     Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.
     Oncologist. 2021;26:290-e545.
     PubMed     Abstract available
     
     
     
114. JIAO XD, Liu K, Xu M, Yu G, et al
     Metastatic Low-Grade Sarcoma with CARS-ALK Fusion Dramatically Responded to Multiple ALK Tyrosine Kinase Inhibitors: A Case Report with Comprehensive Genomic Analysis.
     Oncologist. 2021;26:e524-e529.
     PubMed     Abstract available
     
     
     March 2021
115. ROSS JS, Sokol ES, Moch H, Mileshkin L, et al
     Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
     Oncologist. 2021;26:e394-e402.
     PubMed     Abstract available
     
     
     
116. WANG Y, Chen Z, Han X, Li J, et al
     Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.
     Oncologist. 2021;26:178-181.
     PubMed     Abstract available
     
     
     January 2021
117. DURBIN SM, Zubiri L, Niemierko A, Bardia A, et al
     Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting.
     Oncologist. 2021;26:49-55.
     PubMed     Abstract available
     
     
     
118. CADRANEL J, Liu SV, Duruisseaux M, Branden E, et al
     Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
     Oncologist. 2021;26:7-16.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.